Polaris Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Polaris Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-624,500	Closed	-$64.2M	–	95
2023 Q2	$64.2M	Buy	624,500 +30,600	+5%	+$3.23M	2.41%	9
2023 Q1	$64.8M	Sell	593,900 -3,000	-0.5%	-$332K	2.42%	7
2022 Q4	$67.9M	Buy	+596,900	New	+$49.6M	2.36%	9

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polaris Capital Management's HZNP Position: Q3 2023 in Review

Polaris Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 624,500 shares — an estimated $64.2M sold.

Polaris Capital Management first reported a position in HZNP in Q4 2022 and held it in 3 quarters. The position peaked at $67.9M in Q4 2022. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Polaris Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Polaris Capital Management sold 624,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $64.2M.
Polaris Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 3 quarters.
Polaris Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $67.9M in Q4 2022.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Polaris Capital Management's 13F filing for Q3 2023, filed 30 Oct 2023.